About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs), which are a subset of orphan genetic metabolic diseases. Its cancer product candidates are AG-221 and AG-120, which targets mutated isocitrate dehydrogenase 2 and 1, or IDH2 and IDH1, respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. The lead product candidate in its RGD programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Its AG-221 is an orally available, selective, inhibitor of the mutated IDH2 protein indicated for the treatment of patients with cancers. Its AG-120 is an orally available, selective, inhibitor of the mutated isocitrate dehydrogenase (IDH1) protein for the treatment of patients with cancers. AG-881 is an orally available, selective, brain-penetrant, pan-IDH mutant inhibitor.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: AGIO
- Previous Close: $54.09
- 50 Day Moving Average: $43.80
- 200 Day Moving Average: $47.78
- 52-Week Range: $34.31 - $67.74
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -8.75
- P/E Growth: 0.00
- Market Cap: $2.13B
- Outstanding Shares: 42,234,000
- Beta: 1.97
- Net Margins: -341.56%
- Return on Equity: -53.39%
- Return on Assets: -35.70%
Companies Related to Agios Pharmaceuticals:
- Current Ratio: 7.70%
- Quick Ratio: 7.70%
What is Agios Pharmaceuticals' stock symbol?
Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."
Where is Agios Pharmaceuticals' stock going? Where will Agios Pharmaceuticals' stock price be in 2017?
13 brokers have issued 1 year target prices for Agios Pharmaceuticals' stock. Their predictions range from $45.00 to $90.00. On average, they anticipate Agios Pharmaceuticals' stock price to reach $63.90 in the next twelve months.
When will Agios Pharmaceuticals announce their earnings?
Agios Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, May, 3rd 2017.
What are analysts saying about Agios Pharmaceuticals stock?
Here are some recent quotes from research analysts about Agios Pharmaceuticals stock:
Cowen and Company analysts commented, "Agios ended 2016 with $574MM in cash, enough to last through 2018." (2/16/2017)
According to Zacks Investment Research, "Agios is a development-stage biopharmaceutical company focused on the development of treatments for cancer and rare genetic metabolic disorders. Being a development-stage company, Agios depends heavily on Celgene for revenues, which it earns in the form of collaboration revenues. The collaboration with Celgene is encouraging as it provides Agios funds in the form of upfront, regulatory and commercial milestone payments plus royalties. However, company also depends on Celgene for two of its pipeline candidates – enasidenib and AG-881. Agios’ progress with its pipeline has been impressive. Notably, most of the company's pipeline candidates are in mid and early stages of development and thus several years from entering the market, if at all. Stiff competition is another threat. Shares of the company have underperformed the Medical-Products industry in 2016. The company’s estimates have been going down lately ahead of its Q4 earning." (1/27/2017)
Cann analysts commented, "We are upgrading Agios Pharmaceuticals, a very high quality development-stage biotechnology company with an exceptional management team, from Perform to Outperform, with a $75 12- to 18-month price target." (1/17/2017)
Credit Suisse Group analysts commented, "We view this as positive proof of concept for the inhibition of mutIDH in the treatment of IDHmut glioma. We note AG-120 shows only limited brain penetration, and we view these data providing a positive read-through for AG-881’s development in this indication." (11/21/2016)
Who owns Agios Pharmaceuticals stock?
Agios Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (14.99%), Capital International Investors ** (10.00%), State Street Corp (2.95%), Capital Guardian Trust Co. (1.94%), Columbia Wanger Asset Management LLC (1.51%) and Janus Capital Management LLC (0.91%). Company insiders that own Agios Pharmaceuticals stock include Christopher Bowden, David P Schenkein, Glenn Goddard, John Duncan Higgons, Lewis Clayton Jr Cantley and Scott Biller.
Who sold Agios Pharmaceuticals stock? Who is selling Agios Pharmaceuticals stock?
Agios Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, Clarius Group LLC, Marshall Wace LLP, Asset Management One Co. Ltd., Guggenheim Capital LLC, Arrowpoint Asset Management LLC, Fiera Capital Corp and AQR Capital Management LLC. Company insiders that have sold Agios Pharmaceuticals stock in the last year include David P Schenkein, Lewis Clayton Jr Cantley and Scott Biller.
Who bought Agios Pharmaceuticals stock? Who is buying Agios Pharmaceuticals stock?
Agios Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Capital Guardian Trust Co., State Street Corp, Brown Advisory Inc., FMR LLC, Capital International Ltd. CA, Janus Capital Management LLC, Capital International Inc. CA and Oxford Asset Management.
How do I buy Agios Pharmaceuticals stock?
Shares of Agios Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Agios Pharmaceuticals stock cost?
One share of Agios Pharmaceuticals stock can currently be purchased for approximately $50.40.